Scroll Back to Top

June 3-7 | Chicago, IL | Booth #24085

Join us at the 2022 ASCO Annual Meeting


Our experts are leveraging breakthrough science, clinical data and patient insights to power better decisions and improve patient outcomes across the cancer spectrum.

 

Labcorp Oncology accepted posters and publications

TitleFirst AuthorFormatTrackDateTime
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real world dataGrant HoggPosterHematologic MalignanciesSaturday
June 4, 2022
8:00 AM -
11:00 AM CDT
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHCSarabjot Pabla​PosterDevelopmental Therapeutics—ImmunotherapySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
Comprehensive genomic profiling: insights into diagnostic value and treatment strategy​Michelle ShillerPublicationDevelopmental Therapeutics—Molecularly Targeted Agents and Tumor BiologySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistanceHirotaka MiyashitaPosterDevelopmental Therapeutics—ImmunotherapySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), pharmacodynamic (PD) resultsAnna Di GiacomoPosterDevelopmental Therapeutics—Molecularly Targeted Agents and Tumor BiologySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
Justifying integration of liquid biopsy into routine molecular diagnostics to complement tissue genomic ​profiling: Experience at Fox Chase Cancer CenterDon A. BladwinPublicationDevelopmental Therapeutics—Molecularly Targeted Agents and Tumor BiologySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancersJacob AdashekPosterDevelopmental Therapeutics—ImmunotherapySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
A Multicenter, Open Label, Phase 1a/b Study of HC-7366, a Modulator of Integrated Stress Response (ISR) Kinase GCN2 in Subjects with Advanced Solid TumorsMeredith PelsterPosterDevelopmental Therapeutics—Molecularly Targeted Agents and Tumor BiologySunday
June 5, 2022
8:00 AM -
11:00 AM CDT
Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC) Mary K. NeslinePublication Monday
June 6, 2022
8:00 AM -
11:00 AM CDT